[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
Six weeks into Testing the Waters. Here's where things actually stand.
FDA INTERACT meeting: done. IND protocol: in development. University of Utah Health: planned to be the primary clinical site. DECODE has answered 13 real questions about Fabry disease so far, and our LinkedIn Tuesdays are now team introductions.
If you've been reading since Day 1 — thank you. If you just found us — welcome, and there's a lot to catch up on.
Reply with the one thing about Glafabra you still want explained. We'll make sure it gets its own post.
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0